In addition, targeting inflammatory or neurodegenerative mediators, immunotherapy using drugs such as granulocyte-macrophage colony-stimulating factor (GM-CSF) is promising to reduce TDP-43-induced neuroinflammation and motor neuron death, which may slow ALS progression and enhance patient survival (160). Here, TARDBP is linked to amyotrophic lateral sclerosis.